SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Gilead Science (GILD) Followers
An SI Board Since March 1996
Posts SubjectMarks Bans Symbol
961 87 0 GILD
Emcee:  SybilNicolas Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
811* Net profit 61 cents per share * Revenue increases 29 pct to $1.65 billion LOS MoneyPenny-7/21/2009
810Markets not impressed so far. <i>8:32AM Gilead Sciences' Phase III Dtom pope-5/8/2009
809Here are some data on the HIV market disclosed on GILD’s CC: siliconinvestor.coDewDiligence_on_SI-4/22/2009
808CS: Gilead Sciences (GILD) OUTPERFORM [V] M. Aberman CP: US$ 43.73 TP: US$ 54 CAmopgcw-4/22/2009
807CS: Gilead Sciences (GILD) Outperform [V] M. Aberman CP: US$ 44.70 TP: US$ 54 CAmopgcw-4/3/2009
806Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period tnsaf-4/1/2009
805Mylan reports approval of generic HIV drug Truvada Mylan says it received tentattnsaf-3/31/2009
804European CHMP Adopts Negative Opinion on Aztreonam Lysine Posted March 19, 2009tnsaf-3/21/2009
803The acquisition is immediately accretive to cash EPS (as opposed to GAAP EPS). RDewDiligence_on_SI-3/13/2009
802CS: Conclusion: On first blush, we believe the CV Therapeutics is relatively expmopgcw-3/13/2009
801Gilead Outlines R&D Priorities for 2009 - Progress in Clinical Development Htnsaf-1/27/2009
800For those who chart this stock has an interesting chart pattern going. I have nAugustus Gloop-1/7/2009
799Gilead Sciences Files Patent Infringement Lawsuit Against Teva Pharmaceuticals Ftnsaf-12/12/2008
798Gilead HIV Drug Gets Boost From U.S. Elizabeth Trotta 11/03/08 - 05:48 PM EST Ttnsaf-11/4/2008
797Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(tnsaf-11/2/2008
796Gilead Sciences 3rd-quarter profit rises 27 pct Thu Oct 16, 2008 7:20pm EDT * Gitnsaf-10/16/2008
795Gilead Cystic Fibrosis Drug Rejected by FDA 09/17/08 - 12:27 AM EDT Adam FeuerDoc Bones-9/18/2008
794Growth Amid Pharma Cutbacks Biotech firm Gilead adds jobs, while UCB and Abbottsim1-9/1/2008
793Gilead Sciences starts clinical trial of another HIV drug San Francisco Businesstnsaf-7/22/2008
792CS: Gilead Sciences (GILD) Outperform [V] M. Aberman CP: US$ 55.40 TP: US$ 60 CAmopgcw-7/19/2008
791Gilead shares fall on 2Q report, growth concerns Friday July 18, 11:32 am ET Giltnsaf-7/18/2008
790Two flu drugs help kids equally well: Japan study Thu Jul 3, 2008 3:24pm EDT WAtnsaf-7/4/2008
789Gilead Announces Interim 12-Month Phase III Study Results for Aztreonam Lysine ftnsaf-6/13/2008
788<b>Gilead Buys Hypertension Drug Candidate</b> thestreet.com Elizaidos-5/31/2008
7878:31AM Gilead Sciences says data from pivotal phase III studies of its Letairis tnsaf-5/29/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News